CPA
ENTA icon

Capital Performance Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Capital Performance Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-63
Closed -$653 – 933
2024
Q3 		$653 Buy
+63
New +$824 ﹤0.01% 2122

Other funds holding ENTA

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Performance Advisors's ENTA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2024, closing a stake of 63 shares — an estimated $653 sold.

Capital Performance Advisors first reported a position in ENTA in Q3 2024 and held it in 1 quarter. The position peaked at $653 in Q3 2024. 107 funds tracked by Wall St. Rank hold ENTA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Enanta Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 63 Enanta Pharmaceuticals shares in Q4 2024, an estimated $653.
  • Capital Performance Advisors first reported a position in Enanta Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Enanta Pharmaceuticals position peaked at $653 in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.